Infectious Diseases

Rapidly advance your infectious disease vaccine or therapy to market.

Infectious diseases are a threat to global health and way of life everywhere. Time is of the essence when it comes to developing safe and effective infectious disease vaccines and treatments.  In addition to recent pandemic outbreaks caused by viral infections, more treatment-resistant bacterial and fungal infections are increasing.

If your goal is to mitigate emerging threats and advance human health, you need thoughtful planning and conduct for successful clinical development. Veristat’s scientific-minded infectious disease experts are devoted to helping you navigate this critical and challenging landscape. In the past 5 years, our global operations teams have conducted over 170 clinical trials and consulting projects for Infectious Disease treatments and vaccines.

Developing an infectious disease therapy or vaccine?

Rapid Development of Vaccines and Therapies for Infections

Whether you aim to prevent or combat a viral, bacterial, fungal, or parasitic infection, Veristat global clinical trial and consulting experts can make a difference in your study’s success. Our teams understand the nuances and difficulties involved with treating infectious diseases, have deep experience executing vaccine trials, and are adept with  rapid response to global pandemics that arise, such as the recent  COVID-19 response.

Veristat scientific experts are poised to help:

Rapidly advance your clinical trial to its next milestone.
Reliably achieve regulatory success with regulatory consulting advice, marketing application support, and regulatory publishing.

Gain trusted strategic advice from scientific experts across all disciplines along the clinical development and commercialization pathway.
Ensure ongoing safety for marked products with Post-Market Pharmacovigilance.

Case Study: Collaboration for a Successful COVID-19 Vaccine Program

Learn how Veristat supported HIPRA, a European multinational pharmaceutical company, with a full range of clinical trial services that culminated in EMA approval for HIPRA’s BIMERVAX^® COVID-19 vaccine. Having specialized in veterinary vaccines over its 50 years, HIPRA relied on Veristat’s extensive human vaccine experience to help the company swiftly progress through its clinical trials.